Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Abbott

Abbott Laboratories' Q2 2026 Earnings: What to Expect

Abbott Laboratories is scheduled to report its second-quarter results in July, and analysts expect a single-digit earnings rise.

Barchart

Ultrahuman seeks to define: M2 Live keeps your metabolic health close with a small sensor

Ultrahuman launches M2 Live with Abbott's Lingo biosensor to help users take their glucose (metabolic health) more seriously with a continuous monitor.

Android Central

Hate giving blood? Samsung’s latest VR demo will help you meditate while donating — and it’s given me some ideas

Samsung’s XR headset might help you relax the next time you give blood, thanks to VR meditation.

TechRadar

From analysis to the latest developments in health,
read the most diverse news in one place.

MiniMed Group Q4 Earnings Call Highlights

MiniMed Group (NASDAQ:MMED) reported record fiscal 2026 revenue and outlined a slate of product launches it said will support faster growth in fiscal 2027, as management held the company’s first earnings call as a standalone public company following its March IPO. Chief Executive Officer Que Dallar

MarketBeat

3 Ultra-Reliable Dividend Kings Trading at Bargain-Basement Prices

These beaten-down Dividend Kings, trading near their 2026 lows, offer income, rebound potential, and Wall Street-backed upside for patient investors.

Barchart

Abbott Laboratories Stock Is Getting Decimated, But the Smart Money Senses Opportunity

While ABT stock appears poised to reach the year’s halfway mark in ignominy, the options market is quietly signaling a possible recovery.

Barchart

Gen X is the most indebted generation in America. Their employers can fix that

Student loan matching programs are on the books. Does your company have one?

Fortune

Read news from The Economist, FT, and more,
with one subscription

Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell

See the recent insider activity surrounding Okta, Micron Technology, and Abbott Laboratories, and what these moves signal to investors.

MarketBeat

What to know about Kyle Diamantas, the new acting FDA commissioner

The ex-lawyer who Trump described as ‘very talented’ was previously deputy commissioner for food at the FDA

The Guardian - US

Abbott Stock Is Trading at 52-Week Lows but Insiders Are Gobbling Up Shares of This Blue-Chip Dividend Payer

Abbott’s business and dividend story remain intact even as the stock trades near 52‑week lows.

Barchart

FDA finds US infant formula supply is ‘safe’ after examining 300 samples in Operation Stork Speed

The review was conducted as part of the Food and Drug Administration’s Operation Stork Speed project

The Independent UK

US infant formula supply is 'safe,' FDA says after looking for potential contaminants

Federal health officials said a new analysis of U.S. infant formula found reassuringly low levels of heavy metals, pesticides and other potential contaminants

The Independent UK

This Boring Dividend King Might Be the Safest Pick to Add to Your Portfolio

Abbott Labs is a balance of income and growth.

Barchart

Abbott Stock Crash: Rebound Could Be Coming Fast

Abbott Laboratories' stock price sell-off is overextended in mid-April, creating an opportunity that income investors will not want to miss.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?

Abbott Laboratories' recent stock price dip contrasts with its strong Medical Devices division, creating a noteworthy opportunity for dividend investors.

Barchart

Comparing 2 Healthcare Giants: Which Dividend Aristocrat Will Keep Paying Out for Generations to Come?

Johnson & Johnson offers scale and stability, but Abbott’s cheaper valuation, higher yield, and stronger upside make it the more attractive pick now.

Barchart

Buy the Dip: These 3 Over-$100 Stocks Just Hit New 52-Week Lows

Among the 128 new 52-week lows on the NYSE on Tuesday, there were five with share prices of $100 or higher. Not all of them are worth buying on the dip. We rate three that could be.

Barchart

This Dividend King Is Down 26%. When Will It Bounce Back?

Abbott Laboratories is down 26% from its 52-week high due to a soft quarter. With 54 consecutive years of dividend hikes and guidance calling for mid-single-digit organic sales growth plus 10% EPS expansion, the Dividend King seems discounted, but the question is, can it rebound?

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Abbott Earnings Preview: What to Expect

Abbott is expected to announce its first-quarter results soon, and analysts are projecting single-digit EPS growth.

Barchart

3 High Dividend Growth Kings for Generations of Income That Are Still Rated ‘Buy’

These 3 Dividend Kings combine steady businesses, rising dividends, and solid upside potential for long-term income investors.

Barchart

This Dividend King With a 54-Year Dividend Streak Is Down 13% YTD. Time to Buy the Dip?

This Dividend King is suddenly on sale. Should you buy the dip?

The Independent UK

Patients alarmed after glucose monitors used by diabetics are recalled after links to 7 deaths

Abbott recalled certain sensors used in its FreeStyle Libre 3 and FreeStyle Libre 3 Plus systems, warning they could produce falsely low glucose readings

Budget and the Bees

What to Know About Recent FDA Alerts Involving Glucose Monitors in 2026

For millions living with diabetes, a continuous glucose monitor (CGM) is more than technology. It is a lifeline that provides safety in an unpredictable world. These devices allow you to sleep without fear and eat without complex math. However, high-level FDA alerts can vanish that sense of security instantly. False…

The Independent UK

Coworkers of different generations mentor each other to reduce workplace misunderstandings

With at least five generations participating in the U.S. workforce, coworkers can at times feel like they speak different languages

The Independent UK

New implant for heart failure patients to be rolled out across the NHS

The British Heart Foundation estimates that more than a million people in the UK are living with heart failure

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.